Form 4: Indivior CSO Granted Significant Equity Awards

Indivior Pharmaceuticals' Chief Scientific Officer, Christian Heidbreder, received significant equity awards, including Restricted Stock Units and Performance Stock Units.

Summary

• Christian Heidbreder, Chief Scientific Officer of Indivior Pharmaceuticals, Inc., reported the acquisition of equity awards.
• On February 10, 2026, Heidbreder was granted 33,622 Restricted Stock Units (RSUs) of Indivior common stock at a price of $0 per unit.
• These RSUs represent a contingent right to receive one share per unit and will vest in three equal annual installments starting February 10, 2027, contingent on continued service.
• On February 9, 2026, performance conditions were certified for a conditional award of 132,565 Performance Stock Units (PSUs) initially granted on March 3, 2023.
• These PSUs are set to vest on March 3, 2026, also subject to continued employment.
• Following these transactions, Heidbreder beneficially owns 190,762 shares of common stock and 132,565 derivative Performance Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices and the achievement of performance conditions for a significant equity award, which aligns executive incentives with company performance.

Positives

• Grant of 33,622 Restricted Stock Units (RSUs) to the Chief Scientific Officer, aligning executive incentives with shareholder value.
• Certification of performance conditions for 132,565 Performance Stock Units (PSUs), indicating achievement of company goals.
• The vesting schedules for both RSUs and PSUs incentivize long-term commitment and performance from a key executive.

Negatives

• No immediate cash proceeds for the executive from these grants, as they are equity awards with future vesting.

Risks

• The vesting of these equity awards is contingent on the reporting person's continued service with the Issuer, posing a risk of forfeiture if employment ceases.
• The value of the awards upon vesting is subject to the future market price of Indivior Pharmaceuticals, Inc. common stock.

Future Outlook

The vesting schedules for the granted RSUs and PSUs extend into 2027, indicating a long-term incentive structure for the Chief Scientific Officer.

Management Comments

• Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.
• On March 3, 2023, the Reporting Person was granted a conditional award for 132,565 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Scientific Officer are standard practice in the pharmaceutical industry to attract, retain, and motivate talent, particularly given the long development cycles and intellectual property focus. These grants align executive interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the pharmaceutical sector often include a mix of RSUs and PSUs, similar to this grant.
• The vesting schedules, extending over several years, are typical for incentivizing long-term commitment and performance in an industry with lengthy R&D timelines.
• The use of performance conditions for PSUs is a common best practice to link executive pay directly to the achievement of strategic corporate objectives, such as drug development milestones or financial targets, seen in companies like Pfizer or Merck.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the Chief Scientific Officer's interests with long-term shareholder value through equity ownership and performance-based incentives.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• Vesting of 132,565 Performance Stock Units on March 3, 2026, subject to continued employment.
• First installment vesting of 33,622 Restricted Stock Units on February 10, 2027, with subsequent installments annually thereafter, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While positive for executive retention and alignment, it does not present new information that would fundamentally alter the company's valuation or strategic outlook to warrant a change in investment recommendation. It confirms ongoing executive incentives.

Keywords

Indivior Pharmaceuticals, INDV, Christian Heidbreder, Chief Scientific Officer, Form 4, SEC filing, equity award, Restricted Stock Units, RSUs, Performance Stock Units, PSUs, insider transaction, executive compensation, stock grant